[Breast cancer. Individualized therapy concepts].
Personalized medicine in the sense of individualized therapy concepts plays an important role in breast cancer. In early breast cancer the molecular subtypes luminal A and B and basal-like are important for planning adjuvant systemic therapy. Prognostic and predictive markers, such as hormone receptor status, HER2, Ki-67, uPA/PAI-1 or multiple gene tests, such as Oncotype DX® currently allow avoidance of an over therapy or under therapy. In early and also advanced breast cancer there are an increasing number of new targeted therapies which represent an augmentation of standard endocrine and chemotherapy and in the future could at least partially replace them. As a whole the therapy regimens for breast cancer have become more complex due to the inclusion of molecular information, new therapies and the withdrawal of conventional treatment concepts. Decisive for the future will be the confirmation of this development by modern study concepts contemporarily with adequate evidence. It could then be expected that a personalized therapy for early breast cancer and in particular adjuvant chemotherapy would only be used for those patients for whom it is really necessary. In advanced stage disease there is justified hope that the survival time in the sense of a chronic disease can be improved by the use of targeted therapy.
Brustzentrum, Frauenklinik Großhadern, Universität München, Marchioninistr. 15, 81377, München. nadia.harbeck@med.uni-muenchen.de
N
N
Harbeck
R
R
Wuerstlein
D015415:Biomarkers / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends*; D057285:Precision Medicine / Q000379:methods*
D015415:Biomarkers; D005819:Genetic Markers